Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Phase 3 win for Protagonist Therapeutics with oral plaque psoriasis drug
ICONIC-LEAD study showed icotrokinra, a peptide drug blocking IL-23 receptor, significantly cleared psoriatic plaques. 65% of patients achieved clear skin (IGA 0 or 1) at week 16 vs. 8% placebo. 50% achieved PASI90 vs. 4% placebo. Protagonist earned $165 million in milestone payments. Icotrokinra aims to be as effective as injectable therapies but via oral route.
New phase 3 data of JNJ-2113 for plaque psoriasis in patients aged 12 years, older
Positive phase 3 data for JNJ-2113 (icotrokinra) showed significant skin clearance in moderate-to-severe plaque psoriasis patients aged 12 and older, with 64.7% achieving IGA 0/1 and 49.6% PASI 90 at week 16 compared to placebo. The results validate JNJ-2113's potential as a best-in-class oral treatment.
Ultromics obtains Breakthrough Device FDA clearance for its Cardiac Amyloidosis screening
EchoGo® Amyloidosis, an AI-powered tool, aids in detecting Cardiac Amyloidosis with 84.5% sensitivity and 89.7% specificity, supported by Janssen and Pfizer. Early detection is crucial for therapeutic benefits, addressing diagnostic challenges in underdiagnosed conditions.
Merck and J&J Partner on Digital Display Labels for Clinical Trials
Merck and Johnson & Johnson collaborate to modernize pharma with digital display labels, promising real-time updates, multilingual support, and enhanced data collection, despite higher costs and integration challenges.
Positive Phase 3 Results Announced for JNJ-2113 Treatment of Psoriasis
Protagonist Therapeutics announces positive phase 3 trial results for JNJ-2113, an oral peptide for moderate-to-severe psoriasis, showing significant skin clearance and tolerability. The ICONIC-LEAD and ICONIC-TOTAL studies demonstrated efficacy and safety, with 74.1% achieving IGA scores of 0/1 and 64.9% achieving PASI 90 by Week 24. Further studies on psoriatic arthritis and ulcerative colitis are planned for 2025.
JNJ-2113 Shows Promising Phase 3 Results for Plaque Psoriasis
Protagonist Therapeutics announced positive phase 3 results for JNJ-2113, an oral peptide targeting IL-23 receptor, showing significant skin clearance in moderate to severe plaque psoriasis, with a favorable safety profile.
FDA Grants Breakthrough Therapy Designation for Nipocalimab to Treat Sjögren Disease
The FDA granted breakthrough therapy designation to nipocalimab (Johnson & Johnson) for treating moderate-to-severe Sjögren disease (SjD), the first for this condition. SjD, a chronic autoantibody disease, primarily causes dry eyes and mouth, often coexisting with rheumatoid arthritis and lupus. Nipocalimab, an FcRn blocker, showed positive results in a phase 2 study, with improvements in disease activity and symptoms like dryness. A phase 3 study is ongoing, aiming to address the disease's underlying causes and improve patient outcomes.
Related Clinical Trials:
J&J pill clears skin in two late-stage psoriasis studies
Johnson & Johnson's experimental pill, icotrokinra, developed with Protagonist Therapeutics, showed significant skin clearance in 66% of moderate-to-severe plaque psoriasis patients after four months in a Phase 3 trial. The drug aims to match injectable treatments' effectiveness with oral convenience, targeting the IL-23 receptor. While efficacy appears comparable to Stelara and potentially superior to Sotyktu and Otezla, it may not replace Skyrizi and Tremfya due to lower effectiveness. J&J plans to submit approval applications with detailed results from the ICONIC-LEAD and ICONIC-TOTAL studies.
© Copyright 2024. All Rights Reserved by MedPath